Bicycle Therapeutics PLC
NASDAQ:BCYC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Bicycle Therapeutics PLC
Capital Expenditures
Bicycle Therapeutics PLC
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Capital Expenditures
-$841k
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Capital Expenditures
-$169k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exscientia PLC
NASDAQ:EXAI
|
Capital Expenditures
-ÂŁ26.7m
|
CAGR 3-Years
-106%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Capital Expenditures
-$11m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Capital Expenditures
-ÂŁ5.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Capital Expenditures
-ÂŁ34.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-15%
|
See Also
What is Bicycle Therapeutics PLC's Capital Expenditures?
Capital Expenditures
-841k
USD
Based on the financial report for Mar 31, 2024, Bicycle Therapeutics PLC's Capital Expenditures amounts to -841k USD.
What is Bicycle Therapeutics PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
9%
Over the last year, the Capital Expenditures growth was 95%. The average annual Capital Expenditures growth rates for Bicycle Therapeutics PLC have been 18% over the past three years , 9% over the past five years .